Beta-Blockers and Ultrafiltration Failure

Ho-dac-Pannekeet M.M. , Atasever B. , Struijk D.G. , Krediet R.T. Analysis of ultrafiltration failure in peritoneal dialysis patients by means of standard peritoneal permeability analysis. Perit Dial Int 1997; 17: 144–50.

Heimbürger O. , Waniewski J. , Werynski A. , Tranæus A. , Lindholm B. Peritoneal transport in CAPD patients with permanent loss of ultrafiltration capacity. Kidney Int 1990; 38: 495–506.

Hendriks PMEM , Ho-dac-Pannekeet M.M. , van Gulik ThM , Struijk D.G. , Phoa SSKS , Sie L.H. Peritoneal sclerosis in chronic peritoneal dialysis patients: analysis of clinical presentation, risk factors, and peritoneal transport kinetics. Perit Dial Int 1997; 17: 136–43.

Davies S.J. , Brown B. , Bryan J. , Russell G.I. Clinical evaluation of the peritoneal equilibration test: a population-based study. Nephrol Dial Transplant 1993; 8: 64–70.

Monquil M.C.J. , Imholz A.L.T. , Struijk D.G. , Krediet R.T. Does impaired transcellular water transport contribute to net ultrafiltration failure during CAPD? Perit Dial Int 1995; 15: 42–8.

Stegmayr B.G. Beta-blockers may cause ultrafiltration failure in peritoneal dialysis patients. Perit Dial Int 1997; 17: 541–5.

Brown P. , Baddeley H. , Read A.E. , Davies J.D. , McGarry J. Sclerosing peritonitis, an unusual reaction to a β-adrenergic-blocking drug (practolol). Lancet 1974; 2: 1477–81.

Thompson R.P.H. , Jackson B.T. Sclerosing peritonitis due to practolol. Br Med J 1977; 1: 1393–4.

Baxter-Smith D.C. , Monypenny I.J. , Dorricott N.J. Sclerosing peritonitis in a patient on timolol. Lancet 1978; 2: 149.

Clark C.V. , Terris R. Sclerosing peritonitis associated with metoprolol. Lancet 1983; 1: 937.

Oulès R. , Challah S. , Brunner F.P. Case-control study to determine the cause of sclerosing peritoneal disease. Nephrol Dial Transplant 1988; 3: 66–9.

Krediet R.T. , Zemel D. , Imholz A.L.T. , Koomen G.C.M. , Struijk D.G. , Arisz L. Indices of peritoneal permeability and surface area. PeritDialInt 1993; 13(Suppl 2): S31–4.

Loike J.D. , Cao L. , Kuang K. , Vera J.C. , Silverstein S.C. , Fischbarg J. Role of facilitative glucose transporters in diffusional water permeability through J774 cells. J Gen Physiol 1993; 102: 897–906.

Favazza A. , Montanero D. , Messa P. , Antonucci F. , Gropuzzo M. , Mioni G. Peritoneal clearances in hypertensive CAPD patients after oral administration of clonidine, enalapril, and nifedipine. Perit Dial Int 1992; 12: 287–91.

Ripley E.B.D. , Gehr T.W.B. , Kish C.W. , Sica D.A. Hormonal, blood pressure and peritoneal transport response to short-term ACE inhibition. Perit Dial Int 1994; 14: 378–83.

Mailloux L.U. , Schwartz C.D. , Onesti G.O. Peritoneal dialysis for refractory congestive failure. JAMA 1967; 199: 873–8.

Malack M. Peritoneal dialysis for intractable heart failure in acute myocardial infarction. Am J Cardiol 1972; 29: 61–3.

Bajo M.A. , Selgas R. , Jimenez C. , Del Peso G. , Fernandez Reyes M.J. , Dapena F. CAPD for treatment of ESRD patients with ascites secondary to liver cirrhosis. In: Khanna R. , ed. Advances in peritoneal dialysis. Toronto: Peritoneal Dialysis Publications, 1994; 10: 73–6.

Burroughs A. , Jenkins W.J. , Sherlock S. , Dunk A. , Walt R.P. , Osuafor T.O.K. Controlled trial of propranolol for the prevention of recurrent variceal hemorrhage in patients with cirrhosis. N Engl J Med 1983; 309: 1539–42.

Lebrec D. , Poynard T. , Bernuau J. , Bercoff E. , Nouel O. , Capron J.P. A randomized controlled study of propranolol for prevention of recurrent gastrointestinal bleeding in patients with cirrhosis: a final report. Hepatology 1984; 4: 355–8.

Kiire C.F. Controlled trial of propranolol to prevent recurrent variceal bleeding in patients with non-cirrhotic portal fibrosis. Br Med J 1989; 298: 1363–5.

Lebrec D. , Houel O. , Corbic M. , Benhamou J-P Propanolol a medical treatment for portal hypertension? Lancet 1980; 1: 180–2.

Combis J-M , Vinel J-P , Badia P. , Barange K. , Payen J.L. , Combis F. Haemodynamic effects of molsidomine and propranolol in patients with cirrhosis. Br J Clin Pharmacol 1996; 41: 409–13.

Hillon P. , Lebrec D. , Muñoz C. , Jungers M. , Goldfarb G. , Benhamou J-P Comparison of the effects of a cardioselective and a non-selective β-blocker on portal hypertension in patients with cirrhosis. Hepatology 1982; 2: 528–31.

Krediet R.T. Peritoneal anatomy and physiology during peritoneal dialysis. In: Jacobs C. , Kjellstrand C.M. , Kock K.M. , Winchester J.F. , eds. Replacement of renal function by dialysis. 4th ed. Dordrecht: Kluwer, 1996: 146–77.

McHale N.G. , Roddie I.C. The effect of intravenous adrenaline and noradrenaline infusion on peripheral lymph flow in the sheep. J Physiol 1983; 341: 517–26.

McHale N.G. , Roddie I.C. , Thornbury K.D. Nervous modulation of spontaneous contractions in bovine mesenteric lymphatics. J Physiol 1980; 309: 461–72.

Selgas R. , Muñoz J. , Cigarran S. , Ramos P. , L-Revuelta K. , Escuin F. Peritoneal functional parameters after five years on continuous ambulatory peritoneal dialysis (CAPD): the effect of late peritonitis. Perit Dial Int 1989; 9: 329–32.

Nolph K.D. , Ghods A.J. , Van Stone J. , Brown P.A. The effects of intraperitoneal vasodilators on peritoneal clearances. ASAIO Trans 1976; 22: 586–94.

Hirszel P. , Lasrich M. , Maher J.F. Divergent effects of catecholamines on peritoneal mass transport. ASAIO Trans 1979; 25: 110–13.

Brown E.A. , Kliger A.S. , Goffinet J. , Finkelstein F.O. Effect of hypertonic dialysate and vasodilators on peritoneal dialysis clearances in the rat. Kidney Int 1978; 13: 271–7.

Maher J.F. , Shea C. , Cassetta M. , Hohnadel D.C. Isoproterenol enhancement of peritoneal permeability. J Dial 1977; 1: 319–31.

Felt J. , Richard C. , McCaffrey C. , Levy M. Peritoneal clearance of creatinine and inulin during dialysis in dogs: effect of splanchnic vasodilators. Kidney Int 1979; 16: 459–69.